
Yanan Kong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3901661/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect and Safety of Prophylactic Parecoxib for Pain Control of Transarterial Chemoembolization in Liver Cancer: A Single-Center, Parallel-Group, Randomized Trial. Journal of the American College of Radiology, 2022, 19, 61-70.	1.8	5
2	N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nature Communications, 2022, 13, 2672.	12.8	80
3	Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis. EBioMedicine, 2021, 63, 103137.	6.1	44
4	Predictive Nomogram of Subsequent Liver Metastasis After Mastectomy or Breast-Conserving Surgery in Patients With Nonmetastatic Breast Cancer. Cancer Control, 2021, 28, 107327482199741.	1.8	3
5	Ferroptosis is involved in the progression of hepatocellular carcinoma through the circ0097009/miR-1261/SLC7A11 axis. Annals of Translational Medicine, 2021, 9, 675-675.	1.7	52
6	Identification and Validation of Immune-Related Methylation Clusters for Predicting Immune Activity and Prognosis in Breast Cancer. Frontiers in Immunology, 2021, 12, 704557.	4.8	1
7	Melatonin inhibits triple-negative breast cancer progression through the Lnc049808-FUNDC1 pathway. Cell Death and Disease, 2021, 12, 712.	6.3	18
8	Does Mammotome biopsy affect surgery option and margin status of breast conserving surgery in breast cancer?. Gland Surgery, 2021, 10, 2428-2437.	1.1	4
9	Melatonin Regulates Breast Cancer Progression by the lnc010561/miR-30/FKBP3 Axis. Molecular Therapy - Nucleic Acids, 2020, 19, 765-774.	5.1	23
10	Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study. Frontiers in Oncology, 2020, 10, 580241.	2.8	31
11	LGR6 Promotes Tumor Proliferation and Metastasis through Wnt/β-Catenin Signaling in Triple-Negative Breast Cancer. Molecular Therapy - Oncolytics, 2020, 18, 351-359.	4.4	13
12	Diagnostic and prognostic value of circular RNA CDR1as/ciRSâ€7 for solid tumours: A systematic review and metaâ€analysis. Journal of Cellular and Molecular Medicine, 2020, 24, 9507-9517.	3.6	31
13	Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Quantitative Differentiation of Breast Tumors: A Meta-Analysis. Frontiers in Oncology, 2020, 10, 585486.	2.8	22
14	circGNB1 Facilitates Triple-Negative Breast Cancer Progression by Regulating miR-141-5p-IGF1R Axis. Frontiers in Genetics, 2020, 11, 193.	2.3	41
15	CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/β -catenin Signaling. Current Cancer Drug Targets, 2020, 20, 156-165.	1.6	22
16	Hepatitis B virus infection specially increases risk of liver metastasis in breast cancer patients: a propensity-matched analysis. Translational Cancer Research, 2020, 9, 1506-1517.	1.0	6
17	CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression. Epigenomics, 2019, 11, 1163-1176.	2.1	59
18	Survival benefits of computed tomography-guided thermal ablation for adrenal metastases from hepatocellular carcinoma. International Journal of Hyperthermia, 2019, 36, 1002-1010.	2.5	9

Yanan Kong

#	Article	IF	CITATIONS
19	A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study. Diagnostic Pathology, 2019, 14, 35.	2.0	0
20	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. Journal of Vascular and Interventional Radiology, 2019, 30, 349-357.e2.	0.5	21
21	circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Molecular Cancer, 2019, 18, 23.	19.2	149
22	Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 60-69.	3.7	153
23	FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma. Gut, 2018, 67, 395.1-396.	12.1	68
24	AFAP1-AS1 Promotes Epithelial-Mesenchymal Transition and Tumorigenesis Through Wnt/β-Catenin Signaling Pathway in Triple-Negative Breast Cancer. Frontiers in Pharmacology, 2018, 9, 1248.	3.5	54
25	Breast cancer stem cell markers CD44 and ALDH1A1 in serum: distribution and prognostic value in patients with primary breast cancer. Journal of Cancer, 2018, 9, 3728-3735.	2.5	39
26	Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer. Current Cancer Drug Targets, 2018, 19, 74-80.	1.6	7
27	circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression. Theranostics, 2018, 8, 4003-4015.	10.0	199
28	The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast, 2017, 32, 1-6.	2.2	74
29	Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. European Radiology, 2016, 26, 3492-3499.	4.5	29
30	The utility of breast cone-beam computed tomography, ultrasound, and digital mammography for detecting malignant breast tumors: A prospective study with 212 patients. European Journal of Radiology, 2016, 85, 392-403.	2.6	59
31	LGR5 Promotes Breast Cancer Progression and Maintains Stem-Like Cells Through Activation of Wnt/β-Catenin Signaling. Stem Cells, 2015, 33, 2913-2924.	3.2	135
32	Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Letters, 2015, 356, 374-381.	7.2	10
33	Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells. Molecular Cancer Therapeutics, 2014, 13, 1813-1825.	4.1	13
34	Efficient systemic DNA delivery to the tumor by self-assembled nanoparticle. Journal of Nanoparticle Research, 2014, 16, 1.	1.9	2
35	miR-200b and miR-200c as Prognostic Factors and Mediators of Gastric Cancer Cell Progression. Clinical Cancer Research, 2013, 19, 5602-5612.	7.0	152
36	Cytokeratin19-2g2, a Novel Fragment of Cytokeratin19 in Serum, Indicating a More Invasive Behavior and Worse Prognosis in Breast Cancer Patients. PLoS ONE, 2013, 8, e57092.	2.5	8

Yanan Kong

#	Article	IF	CITATIONS
37	A Nation-Wide Multicenter Retrospective Study of the Epidemiological, Pathological and Clinical Characteristics of Breast Cancer In Situ in Chinese Women in 1999 - 2008. PLoS ONE, 2013, 8, e81055.	2.5	10
38	Evaluation of serum HER2 extracellular domain in in metastatic gastric or gastroesophageal junction cancer: Correlation with HER2 status by immunohistochemistry and fluorescence in situ hybridization and clinicopathologic parameters Journal of Clinical Oncology, 2013, 31, 4107-4107.	1.6	0
39	High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. Journal of Cancer Research and Clinical Oncology, 2012, 138, 275-284.	2.5	18